Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2731 in Chronic Rhinosinusitis with Nasal Polyps
CTR20232279Phase 2Completed
- Sponsor
- Jiangsu Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bosakitug in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Jiangsu Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Started Aug 2023; status: completed.
02
Drugs
bosakitug
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20232279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232279.